Immuneering (IMRX) Current Assets (2020 - 2026)
Immuneering (IMRX) posted quarterly Current Assets of $161.4 million for Q1 2026, up 322.47% year-over-year from $38.2 million in Q1 2025, and down 8.42% quarter-over-quarter from $176.2 million in Q4 2025.
Immuneering (IMRX) Current Assets (2020 - 2026) Analysis & Trends
Immuneering's Current Assets history runs 7 years deep, the most recent figure standing at $161.4 million for Q1 2026.
- In Q1 2026, Current Assets rose 322.47% year-over-year to $161.4 million; the TTM figure through Mar 2026 stood at $161.4 million (up 322.47% YoY), while the FY2025 annual figure was $176.2 million, up 345.21% from the prior year.
- Current Assets for Q1 2026 stood at $161.4 million, down from $176.2 million in the prior quarter.
- The five-year high for Current Assets was $229.1 million in Q3 2025, with the low at $27.7 million in Q2 2025.
- The 5-year median for Current Assets is $100.6 million (2023), against an average of $103.4 million.
- Peak annual rise in Current Assets reached 345.21% in 2025, while the deepest fall reached 56.47% in 2025.
- Immuneering's Current Assets stood at $108.7 million in 2022, then declined by 18.08% to $89.1 million in 2023, then sank by 55.56% to $39.6 million in 2024, then surged by 345.21% to $176.2 million in 2025, then slipped by 8.42% to $161.4 million in 2026.
- Business Quant data shows IMRX's Current Assets at $161.4 million in Q1 2026, $176.2 million in Q4 2025, and $229.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | 157.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 157.99 Mn |
| Mar 31, 2026 | 161.41 Mn |
| Dec 31, 2025 | 176.25 Mn |
| Sep 30, 2025 | 229.10 Mn |
| Jun 30, 2025 | 27.73 Mn |
| Mar 31, 2025 | 38.21 Mn |
| Dec 31, 2024 | 39.59 Mn |
| Sep 30, 2024 | 55.26 Mn |
| Jun 30, 2024 | 63.69 Mn |
| Mar 31, 2024 | 74.45 Mn |
| Dec 31, 2023 | 89.08 Mn |
| Sep 30, 2023 | 100.58 Mn |
| Jun 30, 2023 | 111.51 Mn |
| Mar 31, 2023 | 94.23 Mn |
| Dec 31, 2022 | 108.75 Mn |
| Sep 30, 2022 | 120.02 Mn |
| Jun 30, 2022 | 129.17 Mn |
| Mar 31, 2022 | 139.53 Mn |
| Dec 31, 2021 | 152.33 Mn |
| Sep 30, 2021 | 153.31 Mn |